Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals (scientific article)

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

Q24645530

Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity

Q27640463

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Q27641517

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Q27663293

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Q27671696

Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection

Q28293051

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

Q28752503

Antibody neutralization and escape by HIV-1

Q29547345

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Q29547347

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Q29614531

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma

Q40311562

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Q40429324

Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies

Q40682865

Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus

Q41844960

High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies

Q42939116

Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

Q42959357

HIV-1: nature's master of disguise

Q44031352

Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease

Q44636902

The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12.

Q44721938

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

Q45729198

HIV vaccine design and the neutralizing antibody problem

Q46474020

gp41: HIV's shy protein

Q56888060

Broad HIV-1 neutralization mediated by CD4-binding site antibodies

Q36977635

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

Q37033294

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

Q37033400

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma

Q37051645

Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Q37072702

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

Q37247974

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

Q37333772

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region

Q37410792

Specificities of broadly neutralizing anti-HIV-1 sera

Q37667735

The role of antibodies in HIV vaccines

Q37700725

Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor.

Q38943221

Effect of Major Deletions in the V1 and V2 Loops of a Macrophage-Tropic HIV Type 1 Isolate on Viral Envelope Structure, Cell Entry, and Replication

Q39485916

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4

Q39610645

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

Q39684388

Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex

Q39878965

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis

Q40147993

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

Q29618366

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Q29618603

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Q29619015

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Q29619511

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

Q29619512

Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Q30423779

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Q31016954

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10

Q33272711

Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies

Q33274285

Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.

Q33313394

Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120

Q33374701

International network for comparison of HIV neutralization assays: the NeutNet report

Q33410826

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

Q33444658

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

Q33504599

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

Q33504604

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

Q33526340

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

Q33614365

Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables

Q33614495

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

Q33719511

Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution

Q33778466

Characteristics of the earliest cross-neutralizing antibody response to HIV-1.

Q33798076

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant

Q33812812

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

Q33853775

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3)

Q33855093

Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects

Q33888559

Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual

Q33912373

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

Q33937285

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals

Q34047445

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Q34178201

Acute HIV-1 Infection

Q34185814

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

Q34306804

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Q34341843

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Q34342352

Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles

Q34406977

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Q34434854

The immune response during acute HIV-1 infection: clues for vaccine development

Q34614862

A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope

Q34614992

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

Q34619876

A Conserved Determinant in the V1 Loop of HIV-1 Modulates the V3 Loop To Prime Low CD4 Use and Macrophage Infection

Q34741807

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

Q34742533

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

Q34848486

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

Q34937404

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Q34962766

Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions

Q34977075

Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion

Q34977118

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

Q35012462

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

Q35076717

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

Q35101333

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

Q35140032

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

Q35382871

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

Q35857221

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies

Q35857254

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

Q35857268

Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Q35857683

Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1

Q35880498

Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens

Q36138144

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Q36149102

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

Q36365085

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

Q36403587

The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection

Q36483346

4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response

Q36483956

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design

Q36497712

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

Q36725263

Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries

Q36781196

Exploiting the defensive sugars of HIV-1 for drug and vaccine design

Q36802333

Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization

Q36837815

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection

Q36845710

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Q36974754

P433

issue

P407

language of work or name

English

Q1860

P304

page(s)

11502-19

P577

publication date

2011-11-01

P1433

published in

Journal of Virology

Q1251128

P1476

title

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals

P478

volume

Reverse relations

cites work (P2860)

Q55361754	A Bistable Switch in Virus Dynamics Can Explain the Differences in Disease Outcome Following SIV Infections in Rhesus Macaques.
Q30648718	A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling
Q52609661	Advances in HIV-1 Vaccine Development
Q59351009	An HIV-1 broadly neutralizing antibody from a clade C infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses
Q37680009	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.
Q37069430	An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site
Q35641369	Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency
Q26991572	Antibody responses to envelope glycoproteins in HIV-1 infection
Q39108751	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development
Q36447540	Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design
Q34022578	Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination
Q64065083	Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies
Q39108710	B-cell responses to HIV infection
Q34273373	B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
Q38025633	Basic research in HIV vaccinology is hampered by reductionist thinking
Q92280921	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Q33594304	Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
Q27675131	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Q91812746	Broadly Neutralizing Antibodies against HIV: Back to Blood
Q35894094	Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort
Q46683819	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Q36753653	Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women
Q35641018	CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection
Q34229664	Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies
Q53825583	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
Q36495587	Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).
Q39186163	Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies
Q27644501	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Q36878930	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk
Q27674878	Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
Q35043417	Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial
Q36694111	Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop
Q34114798	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies
Q36105782	Cross-reactive broadly neutralizing antibodies: timing is everything
Q38793711	Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques
Q27654848	Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity
Q35060140	Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system
Q42197619	Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
Q89550864	Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques
Q27022652	Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection
Q58763247	Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Q91802349	Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection
Q36388754	Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
Q55356257	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.
Q36171855	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates
Q52561260	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant
Q36294701	Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.
Q35582579	Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses
Q56913214	HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes
Q89602201	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
Q27022055	HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
Q37221386	HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms
Q35640998	HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies
Q41918753	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
Q42270590	HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages
Q47555844	HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis
Q33939974	HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities
Q35140001	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
Q35914311	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates
Q35826509	High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection
Q39108735	Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies
Q27318508	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Q28602877	Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies
Q30234773	Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem
Q57117718	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells
Q34488183	Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library
Q34324992	Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies
Q34455457	Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models
Q37123168	Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.
Q40103798	Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies
Q37499531	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques
Q40409324	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice
Q34177732	Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies
Q41925820	Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.
Q34593647	Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies
Q34298408	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Q36978671	Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
Q34280115	Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum
Q36888400	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor
Q39027406	Lessons from babies: inducing HIV-1 broadly neutralizing antibodies
Q40404860	Low-Cost Peptide Microarrays for Mapping Continuous Antibody Epitopes
Q36239578	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
Q50084407	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
Q53695792	Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11.
Q36978971	Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial
Q33683203	Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques
Q34712503	Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA
Q36760049	Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies
Q36086357	Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity
Q64905315	Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c+ B-cells in the genital tract.
Q89548775	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization
Q38521826	New approaches to HIV vaccine development
Q37634061	Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies
Q33804531	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge
Q42230293	Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines
Q40092127	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
Q39315316	Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B′-infected former plasma donors from China naïve to antiretroviral therapy
Q37741310	Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy
Q56600657	Progress in HIV-1 vaccine development
Q27693849	Progress in HIV-1 vaccine development.
Q35072515	Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development
Q34480254	Rapid Conformational Epitope Mapping of Anti-gp120 Antibodies with a Designed Mutant Panel Displayed on Yeast
Q35973587	Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys
Q100295640	Selection and immune recognition of HIV-1 MPER mimotopes
Q36053810	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses
Q36446733	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site
Q57292375	Structural Rearrangements Maintain the Glycan Shield of an HIV-1 Envelope Trimer After the Loss of a Glycan
Q55401174	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.
Q35142291	Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
Q36973948	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap
Q52718554	Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire
Q37069793	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates
Q38757011	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses
Q59356767	T-cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection
Q35686970	The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection
Q38621582	The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques
Q92561961	The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes
Q36155396	The development of CD4 binding site antibodies during HIV-1 infection
Q38114279	Translational Research Insights From Completed HIV Vaccine Efficacy Trials
Q35868076	Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
Q38764543	Use of broadly neutralizing antibodies for HIV-1 prevention
Q35914306	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates
Q35034268	Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes
Q27025177	Virological features associated with the development of broadly neutralizing antibodies to HIV-1
Q35150820	Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status